Kala Pharmaceuticals submits NDA to FDA for KPI-121 0.25% to treat dry eye disease

Image: Kala Pharmaceuticals has submitted NDA to FDA for KPI-121 0.25% to treat dry eye disease. Photo: courtesy of oldskool photography / Unsplash.